ERBB2 and inflammatory breast carcinoma: In the subgroup of 5 studies [34–37, 39] in which 105 HER2-positive IBC patients were treated with chemotherapy and either trastuzumab or lapatinib, 57 patients achieved a pCR, and the weighted-average pCR rate was numerical highest of 54.3% (95% CI, 44.3%-64.0%).